What is the recommended diagnostic evaluation for suspected polycythemia?

Diagnostic Evaluation for Suspected Polycythemia

Begin with hemoglobin/hematocrit measurement and JAK2 mutation testing—these two tests together capture >97% of polycythemia vera cases and form the foundation of the diagnostic algorithm.

Initial Laboratory Workup

When polycythemia is suspected, the diagnostic approach depends on whether the erythrocytosis is isolated or accompanied by other cytopenias:

Step 1: Confirm Erythrocytosis

• Hemoglobin thresholds: ≥18.5 g/dL in men, ≥16.5 g/dL in women 1
• Hematocrit thresholds: ≥49% in men, ≥48% in women 2
• Alternative criterion: Sustained hemoglobin increase >2 g/dL above baseline, even if not meeting absolute thresholds 1

Step 2: Determine Testing Sequence Based on Presentation

If polycythemia is accompanied by leukocytosis or thrombocytosis (suggesting primary myeloproliferative neoplasm):

• Immediately order JAK2 V617F mutation testing (present in ~95% of PV cases) 1, 3
• Serum erythropoietin level (low in PV, elevated in secondary causes) 1

If polycythemia is isolated (no other cytopenias):

• First exclude secondary causes before genetic testing 4:
  • Oxygen saturation and arterial blood gas (rule out chronic hypoxia)
  • Medication review (androgens, SGLT2 inhibitors, erythropoietin-stimulating agents)
  • Abdominal imaging for erythropoietin-secreting tumors
  • Sleep study if obstructive sleep apnea suspected 3
• Then proceed to JAK2 testing if secondary causes excluded

Major Diagnostic Criteria for Polycythemia Vera

Diagnosis requires BOTH major criteria plus ≥1 minor criterion, OR the first major criterion plus ≥2 minor criteria 1:

Major Criteria:

1. Elevated hemoglobin (≥18.5 g/dL men, ≥16.5 g/dL women) OR hematocrit (≥49% men, ≥48% women) OR other evidence of increased red cell volume
2. Presence of JAK2 V617F or functionally similar mutation (e.g., JAK2 exon 12)

Minor Criteria:

1. Bone marrow biopsy: Hypercellularity with trilineage growth (panmyelosis), prominent erythroid/granulocytic/megakaryocytic proliferation 1
2. Serum erythropoietin: Below normal reference range 1
3. Endogenous erythroid colony formation in vitro 1

Critical Diagnostic Nuances

Bone marrow biopsy is particularly valuable and should be performed when:

• JAK2 mutation is negative but clinical suspicion remains high 5
• Hemoglobin/hematocrit values are borderline or confounded by iron deficiency 1
• Distinguishing early-stage PV from essential thrombocythemia 5

Important caveat: Iron deficiency can mask elevated hemoglobin/hematocrit. In clinical practice, you can make a working diagnosis of PV despite not meeting hemoglobin thresholds if iron deficient, but for research/trial purposes, formal diagnosis requires demonstrating criteria after iron replacement 1.

Serum erythropoietin levels: While low EPO is specific for PV, 20% of PV patients have normal EPO at presentation 5. Normal EPO does not exclude PV—proceed to bone marrow examination if other criteria suggest PV.

Red Cell Mass Measurement

Red cell mass (Cr-51 RCM) is mandatory only when:

• Hemoglobin and hematocrit values are below diagnostic thresholds but clinical suspicion is high 5
• Distinguishing true polycythemia from relative (spurious) polycythemia 4

The 2007 WHO revision deliberately moved away from requiring RCM in all cases because hemoglobin/hematocrit combined with JAK2 testing captures most cases 1.

Common Pitfalls to Avoid

1. Don't order extensive genetic panels initially—JAK2 V617F alone identifies 95% of PV cases 1, 3
2. Don't skip abdominal ultrasound in isolated polycythemia—identifies solid organ pathology in 11% of pediatric cases and can detect erythropoietin-secreting tumors 6
3. Don't dismiss cases with normal oxygen saturation—all true PV patients should have normal saturation, confirming primary disease 7
4. Don't rely solely on EPO levels—20% of PV patients have normal EPO at presentation 5

Additional Testing for Risk Stratification (Post-Diagnosis)

Once PV is diagnosed, obtain:

• JAK2 V617F allele burden: High allele burden increases risk of myelofibrosis progression 2
• Complete blood count with differential: Leukocytosis is an additional thrombosis risk factor 2
• Baseline platelet count: Extreme thrombocytosis (≥1000 × 10⁹/L) increases bleeding risk via acquired von Willebrand disease 3

This algorithmic approach prioritizes excluding life-threatening secondary causes in isolated polycythemia while rapidly identifying primary PV when accompanied by other cytopenias, maximizing diagnostic accuracy while minimizing unnecessary testing 4, 5.